Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
1.880
-0.020 (-1.05%)
At close: Jun 26, 2026, 4:00 PM EDT
1.880
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:00 PM EDT
Jyong Biotech Employees
Jyong Biotech had 27 employees as of December 31, 2025. The number of employees decreased by 4 or -12.90% compared to the previous year.
Employees
27
Change
-4
Growth
-12.90%
Revenue / Employee
n/a
Profits / Employee
-$173,000
Market Cap
138.45M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 27 | - | - |
| Jun 30, 2024 | 31 | - | - |
| Dec 31, 2023 | 31 | -1 | -3.13% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| enGene Therapeutics | 82 |
| Agenus | 81 |
| Connect Biopharma Holdings | 64 |
| PepGen | 56 |
| Genelux | 26 |
| Spero Therapeutics | 25 |
| Coya Therapeutics | 8 |
MENS News
- 4 weeks ago - Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - GlobeNewsWire
- 6 weeks ago - Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - GlobeNewsWire
- 6 weeks ago - Jyong Biotech Annual report: Q4 2025 - Filings
- 2 months ago - Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - GlobeNewsWire
- 3 months ago - Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - GlobeNewsWire
- 4 months ago - Jyong issues strategic corporate update, completes Phase II trial for MCS-8 - TheFly
- 4 months ago - Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - GlobeNewsWire
- 5 months ago - Jyong Biotech subsidiary announces phase II data for MCS-8 - TheFly